Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B

Yıl: 2024 Cilt: 6 Sayı: 1 Sayfa Aralığı: 22 - 31 Metin Dili: İngilizce DOI: 10.36519/idcm.2024.311 İndeks Tarihi: 04-04-2024

Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B

Öz:
Objective: This study aimed to determine the predictors for significant hepatic abnormality (SHA), a treatment indication, by assessing demographic, laboratory, and radiological results of chronic hepatitis B (CHB) patients who underwent liver biopsy. Materials and Methods: In this retrospective study, individuals with untreated hepatitis B e-antigen (HBeAg)-negative CHB infection were enrolled. Multivariate analysis modeling was conducted with parameters identified as predictors for SHA in univariate analysis. Optimal threshold levels for variables to predict SHA in patients with chronic hepatitis B were determined based on receiver operating characteristic (ROC) curve analysis. Results: A total of 566 patients with untreated chronic hepatitis B were included in the cohort; 61% (345/566) were male, and the median age was 41 years (interquartile range [IQR]=34-50). Notably, 36.9% (209/566) had SHA. In the multivariate analysis, utilizing different models, age, gender, HBV-DNA, LDL, ALT, and platelet count were identified as the most reliable predictors for SHA in CHB patients. For predicting SHA, the area under the ROC curve values of HBV-DNA, AST, and ALT were 0.704 (sensitivity=62.8%, specificity=76.2%; p<0.0001), 0.747 (sensitivity=51.9%, specificity=88.9%; p<0.0001), and 0.737 (sensitivity=68.6%, specificity=68.4%; p<0.0001), respectively. Conclusion: In our study, age, male gender, ALT, AST, HBV-DNA, LDL cholesterol, platelet count, and FIB-4 score were independent predictors of SHA in HBeAg-negative chronic hepatitis B. The most sensitive parameters for SHA were LDL and ALT. The most specific param- eters were age, AST, and APRI score. SHA may occur in patients with high HBV-DNA levels, even if ALT values are normal in HBeAg-negative patients.
Anahtar Kelime: chronic hepatitis B fibrosis score HAI score HBV- DNA ALT

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1 World Health Organization Fact sheets: Hepatitis B [Internet]. Geneva: World Health Organization (WHO). [cited August 01, 2023]. Available from: https://www.who.int/news-room/factsheets/detail/hepatitis-b
  • 2 Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. [CrossRef]
  • 3 Türkiye Viral Hepatit Önleme ve Kontrol Programı: 2018-2023 [Internet]. Ankara: T.C. Sağlık Bakanlığı. [cited November 28, 2023]. Available from: https://hsgm.saglik.gov.tr/depo/Yayin- larimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf
  • 4 Abdo AA, Bzeizi KI, Babatin MA, AlSohaibani F, AlMana H, Alsaad KO, et al. Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. J Clin Gastroenterol. 2014;48(6):e50-6. [CrossRef]
  • 5 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83. [CrossRef]
  • 6 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. [CrossRef]
  • 7 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, et al. SASLT practice guidelines for the management of hepatitis B virus - An update. Saudi J Gastroenterol. 2021;27(3):115-26. [CrossRef]
  • 8 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98. [CrossRef]
  • 9 Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliği [Internet]. Ankara: Sosyal Güvenlik Kurumu (SGK). [cited February 10, 2024]. Available from: https://www.sgk.gov.tr/Duyuru/Detay/27072022-SUT-Degisiklik-Tebligi-Islenmis-Guncel-2013-S UT-2022-07-27-05-04-57
  • 10 Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-9. [CrossRef]
  • 11 Özdemir YE, Salim Doğdaş E, Demir AS, Borcak D, Canbolat Ünlü E, Sezen Aİ, et al. Relationships between liver histopathology with biochemical parameters, and hepatitis B virus-DNA in chronic hepatitis B infection. Viral Hepat J. 2023;29(2):75-80. [CrossRef]
  • 12 Diktas H, Karacaer Z, Özturk II, Cicek H. Comparison of relationship between histopathological, serological and biochemical parameters in patients with chronic hepatitis B infection. Postgrad Med J. 2016;92(1094):693-6. [CrossRef]
  • 13 Cheng R, Tan N, Luo H, Kang Q, Xu X. Noninvasive methods for detecting advanced liver fibrosis and cirrhosis in patients with chronic hepatitis B: a single-center retrospective study. Infect Drug Resist. 2023;16:6323-31. [CrossRef]
  • 14 Tao J, Li W, Ma X, Kong S, An Q, Wang X. Diagnostic and prognostic value of aspartate transaminase-to-platelet ratio index, gamma-glutamyl transpeptidase-to-platelet ratio, and fibrosis-4 for compensated hepatitis B-related liver cirrhosis. J Coll Physicians Surg Pak. 2023;33(8):941-3. [CrossRef]
  • 15 Ramírez Mena A, Ngom NF, Tine J, Ndiaye K, Fortes L, Ndiaye O, et al; On Behalf Of The Sen-B Study Group. Prevalence and predictors of liver fibrosis in people living with hepatitis B in Senegal. Viruses. 2022;14(8):1614. [CrossRef]
  • 16 Wang D, Zhang P, Zhang M. Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase. Exp Ther Med. 2017;14(6):5363-70. [CrossRef]
  • 17 Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One. 2012;7(2):e32622. [CrossRef]
  • 18 Yenilmez E, Çetinkaya RA, Tural E. Diagnostic dilemma for low viremia with significant fibrosis; is hepatitis B virus DNA threshold level a good indicator for predicting liver damage? Balkan Med J. 2018;35(4):326-32. [CrossRef]
  • 19 Kang NL, Wu LY, Zheng Q, Yu XP, Hu AR, Guo Y, et al. Determining optimal ALT cut-off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2024;59(5):692-704. [CrossRef]
  • 20 Esmaeelzadeh A, Saadatnia H, Memar B, Mokhtari Amirmajdi E, Ganji A, Goshayeshi L, et al. Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients. Gastroenterol Hepatol Bed Bench. 2017;10(1):39-43.'
APA Tunçer G, geyiktepe-guclu c, Bayramlar O, Atasoy bozan B, C, Sürme S, Çopur B, Güçlü K, Mustafayev K, Ikizceli T, Uzuner E, YILDIRIM M, SENGOZ G, Pehlivanoglu F (2024). Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. , 22 - 31. 10.36519/idcm.2024.311
Chicago Tunçer Gülsah,geyiktepe-guclu ceyda,Bayramlar Osman Faruk,Atasoy bozan Burcu, Cigdem Yucel,Sürme Serkan,Çopur Betül,Güçlü Kadir Görkem,Mustafayev Khalis,Ikizceli Turkan,Uzuner Esen Gül,YILDIRIM Mustafa,SENGOZ GONUL,Pehlivanoglu Filiz Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. (2024): 22 - 31. 10.36519/idcm.2024.311
MLA Tunçer Gülsah,geyiktepe-guclu ceyda,Bayramlar Osman Faruk,Atasoy bozan Burcu, Cigdem Yucel,Sürme Serkan,Çopur Betül,Güçlü Kadir Görkem,Mustafayev Khalis,Ikizceli Turkan,Uzuner Esen Gül,YILDIRIM Mustafa,SENGOZ GONUL,Pehlivanoglu Filiz Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. , 2024, ss.22 - 31. 10.36519/idcm.2024.311
AMA Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. . 2024; 22 - 31. 10.36519/idcm.2024.311
Vancouver Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. . 2024; 22 - 31. 10.36519/idcm.2024.311
IEEE Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F "Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B." , ss.22 - 31, 2024. 10.36519/idcm.2024.311
ISNAD Tunçer, Gülsah vd. "Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B". (2024), 22-31. https://doi.org/10.36519/idcm.2024.311
APA Tunçer G, geyiktepe-guclu c, Bayramlar O, Atasoy bozan B, C, Sürme S, Çopur B, Güçlü K, Mustafayev K, Ikizceli T, Uzuner E, YILDIRIM M, SENGOZ G, Pehlivanoglu F (2024). Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. Infectious diseases and clinical microbiology (Online), 6(1), 22 - 31. 10.36519/idcm.2024.311
Chicago Tunçer Gülsah,geyiktepe-guclu ceyda,Bayramlar Osman Faruk,Atasoy bozan Burcu, Cigdem Yucel,Sürme Serkan,Çopur Betül,Güçlü Kadir Görkem,Mustafayev Khalis,Ikizceli Turkan,Uzuner Esen Gül,YILDIRIM Mustafa,SENGOZ GONUL,Pehlivanoglu Filiz Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. Infectious diseases and clinical microbiology (Online) 6, no.1 (2024): 22 - 31. 10.36519/idcm.2024.311
MLA Tunçer Gülsah,geyiktepe-guclu ceyda,Bayramlar Osman Faruk,Atasoy bozan Burcu, Cigdem Yucel,Sürme Serkan,Çopur Betül,Güçlü Kadir Görkem,Mustafayev Khalis,Ikizceli Turkan,Uzuner Esen Gül,YILDIRIM Mustafa,SENGOZ GONUL,Pehlivanoglu Filiz Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. Infectious diseases and clinical microbiology (Online), vol.6, no.1, 2024, ss.22 - 31. 10.36519/idcm.2024.311
AMA Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. Infectious diseases and clinical microbiology (Online). 2024; 6(1): 22 - 31. 10.36519/idcm.2024.311
Vancouver Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B. Infectious diseases and clinical microbiology (Online). 2024; 6(1): 22 - 31. 10.36519/idcm.2024.311
IEEE Tunçer G,geyiktepe-guclu c,Bayramlar O,Atasoy bozan B, C,Sürme S,Çopur B,Güçlü K,Mustafayev K,Ikizceli T,Uzuner E,YILDIRIM M,SENGOZ G,Pehlivanoglu F "Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B." Infectious diseases and clinical microbiology (Online), 6, ss.22 - 31, 2024. 10.36519/idcm.2024.311
ISNAD Tunçer, Gülsah vd. "Predictors of Significant Histological Hepatic Abnormality in Treatment-Naïve Patients Infected with HBeAg-Negative Chronic Hepatitis B". Infectious diseases and clinical microbiology (Online) 6/1 (2024), 22-31. https://doi.org/10.36519/idcm.2024.311